TC-H 106 structure
|
Common Name | TC-H 106 | ||
---|---|---|---|---|
CAS Number | 937039-45-7 | Molecular Weight | 339.431 | |
Density | 1.2±0.1 g/cm3 | Boiling Point | 627.3±45.0 °C at 760 mmHg | |
Molecular Formula | C20H25N3O2 | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | 333.1±28.7 °C |
Use of TC-H 106Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I HDAC (HDAC 1, 2, and 3, with IC50 values of 150 nM , 760nM, and 370 nM, respectively), demonstrating no activity against class II HDACs.IC50 value: 150 nM (HDAC1), 370 nM (HDAC3), 760nM(HDAC2)Target: HDAC in vitro: Pimelic diphenylamide 106 has preference toward HDAC3 with Ki of 14 nM, 15 times lower than the Ki for HDAC1.Pimelic diphenylamide 106 exhibits weaker inhibitory activities against HDAC 8 with IC50 of 5 μM after a 3-h preincubation with HDAC8. |
Name | N'-(2-aminophenyl)-N-(4-methylphenyl)heptanediamide |
---|---|
Synonym | More Synonyms |
Description | Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I HDAC (HDAC 1, 2, and 3, with IC50 values of 150 nM , 760nM, and 370 nM, respectively), demonstrating no activity against class II HDACs.IC50 value: 150 nM (HDAC1), 370 nM (HDAC3), 760nM(HDAC2)Target: HDAC in vitro: Pimelic diphenylamide 106 has preference toward HDAC3 with Ki of 14 nM, 15 times lower than the Ki for HDAC1.Pimelic diphenylamide 106 exhibits weaker inhibitory activities against HDAC 8 with IC50 of 5 μM after a 3-h preincubation with HDAC8. |
---|---|
Related Catalog | |
Target |
HDAC1:150 nM (IC50) HDAC3:370 nM (IC50) HDAC2:760 nM (IC50) HDAC8:5000 nM (IC50) |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 627.3±45.0 °C at 760 mmHg |
Molecular Formula | C20H25N3O2 |
Molecular Weight | 339.431 |
Flash Point | 333.1±28.7 °C |
Exact Mass | 339.194672 |
PSA | 84.22000 |
LogP | 2.51 |
Appearance of Characters | white solid |
Vapour Pressure | 0.0±1.8 mmHg at 25°C |
Index of Refraction | 1.636 |
Storage condition | -20℃ |
RIDADR | NONH for all modes of transport |
---|
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
Bioorg. Med. Chem. 23 , 5151-5, (2015) Two of the histone deacetylases, TbDAC1 and TbDAC3, have been reported to be essential genes in trypanosomes. Therefore, we tested the activity of a panel of human histone deacetylase inhibitors (HDAC... |
|
Inhibition of Histone Deacetylases Permits Lipopolysaccharide-Mediated Secretion of Bioactive IL-1β via a Caspase-1-Independent Mechanism.
J. Immunol. 195 , 5421-31, (2015) Histone deacetylase (HDAC) inhibitors (HDACi) are clinically approved anticancer drugs that have important immune-modulatory properties. We report the surprising finding that HDACi promote LPS-induced... |
N-(2-Aminophenyl)-N'-(4-methylphenyl)heptanediamide |
Pimelic Diphenylamide |
Heptanediamide, N-(2-aminophenyl)-N-(4-methylphenyl)- |
Pimelic Diphenylamide 106 |
TC-H 106 |